KR20210002472A - 신경병증성 통증을 치료하는 방법 - Google Patents

신경병증성 통증을 치료하는 방법 Download PDF

Info

Publication number
KR20210002472A
KR20210002472A KR1020207028395A KR20207028395A KR20210002472A KR 20210002472 A KR20210002472 A KR 20210002472A KR 1020207028395 A KR1020207028395 A KR 1020207028395A KR 20207028395 A KR20207028395 A KR 20207028395A KR 20210002472 A KR20210002472 A KR 20210002472A
Authority
KR
South Korea
Prior art keywords
oxy
fluorophenyl
phenyl
methyl
prolineamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207028395A
Other languages
English (en)
Korean (ko)
Inventor
위엔 자오
히만슈 나이크
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Publication of KR20210002472A publication Critical patent/KR20210002472A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020207028395A 2018-04-16 2019-04-12 신경병증성 통증을 치료하는 방법 Withdrawn KR20210002472A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658347P 2018-04-16 2018-04-16
US62/658,347 2018-04-16
PCT/US2019/027158 WO2019204136A1 (en) 2018-04-16 2019-04-12 Methods of treating neuropathic pain

Publications (1)

Publication Number Publication Date
KR20210002472A true KR20210002472A (ko) 2021-01-08

Family

ID=68239826

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207028395A Withdrawn KR20210002472A (ko) 2018-04-16 2019-04-12 신경병증성 통증을 치료하는 방법

Country Status (14)

Country Link
US (1) US20210154170A1 (https=)
EP (1) EP3781157A4 (https=)
JP (1) JP2021521227A (https=)
KR (1) KR20210002472A (https=)
CN (1) CN112367990A (https=)
AU (1) AU2019255519A1 (https=)
BR (1) BR112020021101A2 (https=)
CA (1) CA3093401A1 (https=)
EA (1) EA202092482A1 (https=)
IL (1) IL277962A (https=)
MX (1) MX2020010929A (https=)
SG (1) SG11202008681PA (https=)
TW (2) TW202245750A (https=)
WO (1) WO2019204136A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
GB201409851D0 (en) * 2014-06-03 2014-07-16 Convergence Pharmaceuticals Diagnostic method
GB201417497D0 (en) * 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
JP2019537601A (ja) * 2016-11-02 2019-12-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 新規投薬レジメン

Also Published As

Publication number Publication date
JP2021521227A (ja) 2021-08-26
MX2020010929A (es) 2020-11-06
TWI803619B (zh) 2023-06-01
US20210154170A1 (en) 2021-05-27
CA3093401A1 (en) 2019-10-24
AU2019255519A1 (en) 2020-10-01
IL277962A (en) 2020-11-30
SG11202008681PA (en) 2020-10-29
TW202245750A (zh) 2022-12-01
EA202092482A1 (ru) 2021-03-30
BR112020021101A2 (pt) 2021-02-23
CN112367990A (zh) 2021-02-12
EP3781157A1 (en) 2021-02-24
WO2019204136A1 (en) 2019-10-24
EP3781157A4 (en) 2022-01-26
TW201946619A (zh) 2019-12-16

Similar Documents

Publication Publication Date Title
US10934244B2 (en) Compounds for use in treating neuromuscular disorders
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
DE60313330T2 (de) Synergistische Zusammensetzungen enthaltend einen alpha-2-delta-Liganden, kombiniert mit einem PDEV-Inhibitor zur Behandlung von Schmerz
KR20180064373A (ko) 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
JP2010507672A (ja) アルツハイマー病を治療するための方法および組み合わせ治療
KR20150041635A (ko) 시스타티오닌-γ-리아제(ＣＳＥ) 억제제
TW201521722A (zh) 乙醯輔酶ａ羧化酶抑制劑於治療尋常痤瘡之用途
US6774131B1 (en) Remedies for endothelin-induced diseases
JP2009514961A (ja) アンギオテンシンｉｉ受容体ブロッカー、カルシウムチャネルブロッカーおよび他の活性剤の組合せ
KR20210002472A (ko) 신경병증성 통증을 치료하는 방법
JP2023011652A (ja) 新規投薬レジメン
JPH04225917A (ja) 記憶増強剤として有用な５−アリ−ル−４−アルキル−３ｈ−１，２，４−トリアゾール−３−チオン類
HK40046223A (en) Methods of treating neuropathic pain
JP2006522084A (ja) アルツハイマー病治療のためのｇｈ分泌促進物質及びｐｄｅ４阻害剤の組み合わせ
US9265774B2 (en) Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
RU2844953C1 (ru) Способы лечения симптомов расстройства аутистического спектра
JP2019123724A (ja) 代謝型グルタミン酸作動性受容体サブタイプ２の正のアロステリック調節因子またはオルトステリックアゴニストを含む組み合わせ、およびそれらの使用
US20090156609A1 (en) Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperzaine compounds
WO2002051416A1 (fr) Medicaments ameliorant les comportements de la vie courante chez des personnes atteintes de la maladie d'alzheimer
JP2020520933A (ja) 新規な結晶形態
NZ732033B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
HK1105553A (en) Multiple agent therapy for sexual dysfunction

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202